title: Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer.
abstract: OBJECTIVE
  To determine if development of acneiform rash is a predictor of objective response rate with lapatinib.
  
  
  METHODS
  Subanalysis of data from a prospective, phase II study.
  
  
  METHODS
  Academic breast care clinic.
  
  
  METHODS
  Forty-nine treatment-naïve patients with human epidermal growth factor receptor-2 (HER2)-positive locally advanced breast cancer, who were treated with neoadjuvant lapatinib monotherapy for 6 weeks; 47 patients were included in the final analysis.
  
  
  RESULTS
  Of the 49 patients enrolled, 33 (67%) developed a rash of any type, and 26 (55%) had acneiform rash. Of the 26 evaluable patients with acneiform rash (55%), 19 (73%) responded to lapatinib and 7 (27%) did not. Of the 21 evaluable patients without acneiform rash, 11 (67%) responded to treatment and 7 (33%) did not. Thus, no association was found between the occurrence of acneiform rash and response to lapatinib monotherapy.
  
  
  CONCLUSIONS
  This study does not support the development of the acneiform rash as a predictor of clinical efficacy of lapatinib in the treatment of breast cancer.
authors.affiliation: University of Houston College of Pharmacy, Houston, Texas.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Parma
authors.forename: Anne
authors.initials: A
authors.lastname: Pavlick
authors.forename: Rachel
authors.initials: R
authors.lastname: Schiff
authors.forename: C Kent
authors.initials: CK
authors.lastname: Osborne
authors.forename: Jenny C
authors.initials: JC
authors.lastname: Chang
authors.forename: Mothaffar
authors.initials: M
authors.lastname: Rimawi
authors.forename: Meghana V
authors.initials: MV
authors.lastname: Trivedi
mesh_terms: D017486:Acneiform Eruptions / Q000139:chemically induced* / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D005260:Female; D006801:Humans; D000077341:Lapatinib; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011446:Prospective Studies; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
keywords: EGFR; HER2; breast cancer; dermatologic toxicity; lapatinib; rash